Alliance Pharma is pleased to announce the appointment of Masood Khan, PhD, to the position of Vice President, Biopharma Services.
Dr. Khan is an internationally renowned thought leader in the field of regulatory compliant ligand binding assays (LBAs) and has coauthored numerous authoritative reviews on validation of LBA and biomarker assays. He has over 120 publications and presentations, including a book entitled, Ligand-Binding Assays: Development, Validation, and Implementation in the Drug Development Arena, which is widely referenced in the pharmaceutical industry .
Dr. Khan brings over 25 years of unparalleled knowledge of immunoanalytical sciences and technologies to head scientific operations and compliance of the large molecule bioanalyses division at Alliance Pharma. He will specialize on LBAs for pharmacokinetic/toxicokinetic, immunogenicity, and biomarker assessments in preclinical and clinical studies. Prior to joining Alliance Pharma, Dr. Khan established the first Ligand Binding Assay Bioanalytical (LBAB) Department at one of the largest pharmaceutical contract research organizations (CROs) in the world at the time, Phoenix International Life Sciences, Inc., in Montreal, Canada, where he led that department for 9 years . He again spearheaded the rebuilding or creation of similar LBA departments at two other leading CROs, Covance and KCAS Bioanalytical & Biomarker Services. In addition, he has held executive leadership roles at biopharmaceutical companies MedImmune and Neuro-Biotech Corp.
Dr. Khan is a founding member of the Ligand Binding Assay Bioanalytical Focus Group (LBABFG) at the prestigious American Association of Pharmaceutical Scientists (AAPS), where he served on the steering committee for over 8 years and contributed regularly as program organizer, speaker, and panelist. He was instrumental in the formation of the Biomarker Action Plan Committee (APC) in 2007 and is currently actively engaged in various subcommittees geared toward formulating white papers related to Multiplex Biomarker Assay Validation, Biomarker Sample Stability Considerations, and guidance on Pharma-grade kits for biomarkers. Most recently, Dr. Khan led the Commercial Biomarker Kit Validation subcommittee and published a white paper in the journal, Bioanalysis.
“We are very pleased to welcome Dr. Khan during this exciting period of growth for our company,” said Frank Li, PhD, Co-founder and President of Alliance Pharma. “Dr. Khan’s appointment is an additional step toward strengthening the technical and scientific capabilities of our team, and thanks to his expertise and senior management experience, he will be an invaluable asset to Alliance Pharma.”
“I am very excited to join Alliance Pharma, a company that has shown impressive expansion over the last 5 years,” said Dr. Khan. “Today the demand for reliable Bioanalytical services in Biotherapeutic and Biosimilar drug development is growing rapidly. I look forward to strengthening our Biopharma Services to provide the dependable and outstanding large molecule bioanalytical support that our industry needs.”